Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Federal Trade Commission
Boehringer Ingelheim
Chubb
McKesson
Farmers Insurance
Cantor Fitzgerald
UBS
Fish and Richardson

Generated: June 25, 2018

DrugPatentWatch Database Preview

UNIVASC Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Univasc, and what generic alternatives are available?

Univasc is a drug marketed by Ucb Inc and is included in one NDA.

The generic ingredient in UNIVASC is moexipril hydrochloride. There are seven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the moexipril hydrochloride profile page.
Drug patent expirations by year for UNIVASC
Pharmacology for UNIVASC
Synonyms for UNIVASC
(3S)-2-((2S)-N-((1S)-1-Carboxy-3-phenylpropyl)alanyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, 2-ethyl ester, monohydrochloride
(3S)-2-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenyl-d5-propyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic Acid Hydrochloride
(3S)-2-[(2S)-2-[[(1S)-1-ethoxycarbonyl-3-phenyl-propyl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid hydrochloride
(3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid hydrochloride
(3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid;hydrochloride
(S)-2-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid hydrochloride
2-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid hydrochloride
3-Isoquinolinecarboxylic acid, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-, monohydrochloride, (3S-(2(R*(R*)),3R*))-
3-isoquinolinecarboxylic acid, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-(2-((1-ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-, monohydrochloride, (3S-(2(R*(R*)),3R*))-
3-Isoquinolinecarboxylic acid, 2-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-, monohydrochloride, (3S-(2(R*(R*)),3R*))-
586M525
82586-52-5
AB2000483
AC1L1HXF
AKOS016340373
Ambap103775-10-6
AN-36120
API0003416
BS-1007
C27H34N2O7.HCl
CAS-82586-52-5
CHEBI:6961
CHEMBL1200534
CI 925
CI-925
CS-2446
CTK8G1159
D00623
DSSTox_CID_24267
DSSTox_GSID_44267
DSSTox_RID_80137
DTXSID7044267
Femipres
HY-B0378A
JXRAXHBVZQZSIC-JKVLGAQCSA-N
LS-85469
MLS003882580
Moexipril (hydrochloride)
Moexipril HCL
MOEXIPRIL HYDROCHLORIDE
Moexipril hydrochloride (USAN)
Moexipril hydrochloride [USAN]
Moexipril hydrochloride, powder, >=98% (HPLC)
Moexipril hydrochloride, United States Pharmacopeia (USP) Reference Standard
MolPort-003-666-743
NCGC00167834-01
NCGC00263546-01
Perdix
Primoxil
Q1UMG3UH45
RS 10085
RS 10085-197
RS-10085
RS-10085-197
s2079
SC-95143
SCHEMBL40877
SMR002533645
SPM 925
SPM-925
Tox21_112590
Tox21_112590_1
UNII-Q1UMG3UH45
Univasc (TN)

US Patents and Regulatory Information for UNIVASC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ucb Inc UNIVASC moexipril hydrochloride TABLET;ORAL 020312-001 Apr 19, 1995 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Ucb Inc UNIVASC moexipril hydrochloride TABLET;ORAL 020312-002 Apr 19, 1995 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for UNIVASC

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ucb Inc UNIVASC moexipril hydrochloride TABLET;ORAL 020312-002 Apr 19, 1995 ➤ Sign Up ➤ Sign Up
Ucb Inc UNIVASC moexipril hydrochloride TABLET;ORAL 020312-001 Apr 19, 1995 ➤ Sign Up ➤ Sign Up
Ucb Inc UNIVASC moexipril hydrochloride TABLET;ORAL 020312-002 Apr 19, 1995 ➤ Sign Up ➤ Sign Up
Ucb Inc UNIVASC moexipril hydrochloride TABLET;ORAL 020312-001 Apr 19, 1995 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Johnson and Johnson
US Army
Chinese Patent Office
Teva
Fish and Richardson
Cipla
Moodys
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.